205 related articles for article (PubMed ID: 31549386)
21. Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.
Zhao YC; Lin XB; Zhang BK; Xiao YW; Xu P; Wang F; Xiang DX; Xie XB; Peng FH; Yan M
Clin Transl Sci; 2021 Mar; 14(2):702-711. PubMed ID: 33202102
[TBL] [Abstract][Full Text] [Related]
22. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
[TBL] [Abstract][Full Text] [Related]
23. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
[TBL] [Abstract][Full Text] [Related]
24. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
25. Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients.
Hashemizadeh Z; Badiee P; Malekhoseini SA; Raeisi Shahraki H; Geramizadeh B; Montaseri H
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923870
[TBL] [Abstract][Full Text] [Related]
26. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis.
Kirbs C; Kluwe F; Drescher F; Lackner E; Matzneller P; Weiss J; Zeitlinger M; Kloft C
Eur J Pharm Sci; 2019 Apr; 131():218-229. PubMed ID: 30731238
[TBL] [Abstract][Full Text] [Related]
27. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
Zhong X; Tong X; Ju Y; Du X; Li Y
Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
[TBL] [Abstract][Full Text] [Related]
28. Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.
Mangal N; Hamadeh IS; Arwood MJ; Cavallari LH; Samant TS; Klinker KP; Bulitta J; Schmidt S
Clin Pharmacol Ther; 2018 Nov; 104(5):957-965. PubMed ID: 29315506
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
Naujokaitis D; Asmoniene V; Kadusevicius E
Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
[TBL] [Abstract][Full Text] [Related]
30. CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
Zhu L; Brüggemann RJ; Uy J; Colbers A; Hruska MW; Chung E; Sims K; Vakkalagadda B; Xu X; van Schaik RH; Burger DM; Bertz RJ
J Clin Pharmacol; 2017 Feb; 57(2):235-246. PubMed ID: 27432796
[TBL] [Abstract][Full Text] [Related]
31. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
32. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
Owusu Obeng A; Egelund EF; Alsultan A; Peloquin CA; Johnson JA
Pharmacotherapy; 2014 Jul; 34(7):703-18. PubMed ID: 24510446
[TBL] [Abstract][Full Text] [Related]
33. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
34. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Trégouet DA; Amrein C; Boussaud V; Chevalier P; Lillo-Lelouet A; Le Beller C; Laurent-Puig P; Beaune PH; Billaud EM; Loriot MA
Eur J Clin Pharmacol; 2011 Mar; 67(3):253-60. PubMed ID: 21038076
[TBL] [Abstract][Full Text] [Related]
35. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
[TBL] [Abstract][Full Text] [Related]
36. Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations.
You H; Dong Y; Zou Y; Zhang T; Lei J; Chen L; Wang X; Dong Y; Wang T
Int J Clin Pharmacol Ther; 2018 May; 56(5):239-246. PubMed ID: 29393850
[TBL] [Abstract][Full Text] [Related]
37. Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation.
Chen C; Yang T; Li X; Ma L; Liu Y; Zhou Y; Ren H; Cui Y
Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):659-668. PubMed ID: 31041728
[TBL] [Abstract][Full Text] [Related]
38. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
Marks DI; Liu Q; Slavin M
Expert Rev Anti Infect Ther; 2017 May; 15(5):493-502. PubMed ID: 28335642
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
[TBL] [Abstract][Full Text] [Related]
40. CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.
Takahashi T; Mohamud MA; Smith AR; Jacobson PA; Jaber MM; Alharbi AF; Fisher J; Kirstein MN
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0062321. PubMed ID: 34097481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
